New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
10:01 EDTSTJOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abbott (ABT) initiated with a Buy at Evercore ISI... Aldeyra (ALDX) initiated with a Buy at Janney Capital... Black Stone Minerals (BSM) initiated with a Neutral at Credit Suisse... Boston Scientific (BSX) initiated with a Buy at Evercore ISI... Cidara Therapeutics (CDTX) initiated with a Buy at BTIG... Coach (COH) initiated with an Underweight at BB&T... Diplomat Pharmacy (DPLO) initiated with an Outperform at Raymond James... EPIRUS (EPRS) initiated with a Buy at BTIG... Enviva (EVA) initiated with a Buy at Citigroup... General Finance Corp (GFN) initiated with an Outperform at Oppenheimer... Hortonworks (HDP) initiated with an Outperform at Oppenheimer... Jarden (JAH) initiated with a Buy at UBS... Kate Spade (KATE) initiated with a Buy at BB&T... Medtronic (MDT) initiated with a Hold at Evercore ISI... MoneyGram (MGI) initiated with a Neutral at Goldman... Opexa Therapeutics (OPXA) initiated with a Buy at Maxim... Paratek Pharmaceuticals (PRTK) initiated with a Buy at BTIG... Progenics (PGNX) initiated with a Buy at BTIG... Rite Aid (RAD) initiated with a Buy at Mizuho... St. Jude Medical (STJ) initiated with a Buy at Evercore ISI... Starwood Waypoint (SWAY) initiated with an Outperform at Wells Fargo... Talen Energy (TLN) initiated with a Hold at Deutsche Bank... Ulta Salon (ULTA) initiated with a Buy at Buckingham... Vipshop (VIPS) initiated with a Buy at Stifel... Virtu Financial (VIRT) initiated with a Neutral at Citigroup... Vista Outdoor (VSTO) initiated with a Buy at Wunderlich... ZELTIQ (ZLTQ) initiated with a Buy at Northcoast... eBay (EBAY) initiated with a Buy at Topeka.
May 26, 2015
17:45 EDTSTJSt. Jude Medical initiated with a Buy at Evercore ISI
Subscribe for More Information
May 20, 2015
08:09 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
07:16 EDTSTJLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
05:29 EDTSTJSt. Jude Medical announces preliminary results from ILUMIEN I and ILUMIEN II
St. Jude Medical announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with resolution up to 10 times higher than intravascular ultrasound, optical coherence tomography imaging can help improve stent selection and deployment, better support clinical decision-making and improve patient outcomes. In the prospective study to date examining OCTís impact on clinical decisions and their associated outcomes, ILUMIEN I assessed 418 patients suffering stable or unstable angina or non-ST segment elevation myocardial infarction. The studyís 12-month data shows: OCT guidance conducted either pre- or post-PCI altered physician decision-making in 65% of patients; Pre-PCI OCT altered treatment planning in 55% of patients and led to changes in decisions related to stent length and diameter; OCT imaging was associated with a reduction of in-hospital MI when used pre- and post-PCI to change the procedural strategy. The ILUMIEN II study was designed to determine whether OCT guidance results in a comparable degree of stent expansion as IVUS imaging. After an analysis of OCT-guided stenting or IVUS-guided stenting in 940 patients from the ILUMIEN I and ADAPT-DES studies, the degree of stent expansion was found to be comparable between OCT and IVUS imaging. The studyís data shows OCT and IVUS guidance were also associated with comparable rates of major stent malapposition, tissue protrusion and stent edge dissection.
May 19, 2015
08:05 EDTSTJSt. Jude Medical announces Canadian launch of Prodigy Chronic Pain System
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use